Loading...
Market
Which country will first approve Lirafugratinib for FGFR2-driven cholangiocarcinoma by end of 2025?
2
Resolution / Starting Odds
United States • 25%
European Union • 25%
Japan • 25%
Other • 25%
Official announcements from respective national health authorities
Story
Relay and Elevar Sign Licensing Deal for Lirafugratinib in FGFR2-Driven Cholangiocarcinoma, Potentially Worth $500 Million
Dec 3, 2024, 01:04 PM
Relay Therapeutics and Elevar Therapeutics have entered into an exclusive global licensing agreement for Lirafugratinib, a treatment aimed at FGFR2-driven cholangiocarcinoma and other solid tumors. Under the terms of the agreement, Relay Therapeutics is set to receive up to $500 million in total, which includes $75 million in upfront and regulatory milestone payments, as well as up to $425 million in potential commercial milestone payments and tiered royalties in the low-teens percentage range. This collaboration is expected to enhance Relay's oncology pipeline, particularly in addressing challenging cancer types.
View original story
Similar markets
Approved in the US only • 25%
Approved in the US and EU • 25%
Approved in the US, EU, and other regions • 25%
Not approved in any region • 25%
United States • 25%
United Kingdom • 25%
Germany • 25%
Other • 25%
European Union • 25%
Canada • 25%
Japan • 25%
Other • 25%
United States • 25%
European Union • 25%
China • 25%
Other • 25%
Less than 10 • 25%
10-20 • 25%
21-30 • 25%
More than 30 • 25%
United States • 25%
European Union • 25%
Other regions • 25%
No approval by end of 2025 • 25%
United States • 25%
European Union • 25%
China • 25%
Other • 25%
United States • 25%
United Kingdom • 25%
Germany • 25%
Other • 25%
North America • 25%
Europe • 25%
Asia • 25%
Other • 25%
India • 25%
South Africa • 25%
Brazil • 25%
Other • 25%
Johnson & Johnson • 25%
Pfizer • 25%
AstraZeneca • 25%
Roche • 25%